ROIV SEC Filings: 8-K, 10-Q, S-3 & 424B – Roivant Sciences

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

May 20, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Feb 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWRoivant Reports Financial Results for Q2 Fiscal 2026 and Provides Business Updates

Nov 9, 2026

8-K

Roivant and Priovant Announce Positive Phase 3 Results for Brepocitinib in Non-Infectious Uveitis

Oct 21, 2026

8-K

Roivant Sciences Ltd. Announces Voting Results from its 2026 Annual General Meeting of Shareholders

Sep 18, 2026

8-K

Roivant Announces Positive Phase 2 PHocus Results for Mosliciguat in PH-ILD and Initiation of Phase 3 PHrontier Study

Sep 8, 2026

8-K

FDA Approves LISRAYA (brepocitinib) for the Treatment of Dermatomyositis

Aug 28, 2026

8-K

Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis

Aug 27, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 20, 2026

S-3ASR

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Oct 3, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jul 26, 2024

S-3

SHELF | Offering amount: $1,500,000,000.00

Sep 29, 2023

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jun 28, 2023

POS AM

Form POS AM - Post-Effective amendments for registration statement

Sep 29, 2022

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jul 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jul 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jul 29, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jul 29, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Jul 26, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Jul 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Venker Eric (Reporting)

Nov 5, 2026

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

144

Form 144 - Report of proposed sale of securities

Nov 3, 2026

Venker Eric (Reporting)

Oct 30, 2026

144

Form 144 - Report of proposed sale of securities

Oct 28, 2026

Oren Ilan (Reporting)

Oct 27, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 10, 2023

CORRESP

Form CORRESP - Correspondence

Oct 4, 2023

LETTER

Form UPLOAD - SEC-generated letter

Oct 4, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 4, 2022

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 4, 2022

EFFECT

Form EFFECT - Notice of Effectiveness

Oct 4, 2022

Roivant Sciences Ltd. ROIV · SEC Filings